Hexo details U.S. CBD plans as Q3 earnings miss estimates, stock slips

  • 📰 globeandmail
  • ⏱ Reading Time:
  • 36 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 18%
  • Publisher: 92%

Indonesia Berita Berita

Indonesia Berita Terbaru,Indonesia Berita utama

Hexo details U.S. CBD plans as Q3 earnings miss estimates, stock slips GlobeBusiness

Cannabis company Hexo Corp. outlined its plans to enter eight U.S. states with CBD products in 2020 as it reported third-quarter earnings that fell short of expectations, sending its stock lower.

Cannabis is legal for medical and recreational use in several U.S. states, but remains illegal at the federal level south of the border. However, the passage of a U.S. law late last year has allowed for the growing of hemp for the purposes of extracting CBD. Hexo’s quarterly net loss deepened to $7.75 million, from a $1.97-million loss a year earlier, as operating expenses jumped to $24.1 million from $5.3 million during the same period in 2018.The company’s stock on the Toronto Stock Exchange on Thursday slipped as low as $7.78, down 8.8 per cent from $8.53 on Wednesday.

Hexo said Thursday that it still expects to ramp its net revenue to $400 million by its 2020 financial year.

 

Terima kasih atas komentar Anda. Komentar Anda akan dipublikasikan setelah ditinjau.
Berita ini telah kami rangkum agar Anda dapat membacanya dengan cepat. Jika Anda tertarik dengan beritanya, Anda dapat membaca teks lengkapnya di sini. Baca lebih lajut:

 /  🏆 5. in İD

Indonesia Berita Terbaru, Indonesia Berita utama